SE425566B - Forfarande for framstellning av erytromycinderivat och syraadditionssalter derav - Google Patents

Forfarande for framstellning av erytromycinderivat och syraadditionssalter derav

Info

Publication number
SE425566B
SE425566B SE7604052A SE7604052A SE425566B SE 425566 B SE425566 B SE 425566B SE 7604052 A SE7604052 A SE 7604052A SE 7604052 A SE7604052 A SE 7604052A SE 425566 B SE425566 B SE 425566B
Authority
SE
Sweden
Prior art keywords
procedure
preparation
additional salts
erythromycin derivatives
acid additional
Prior art date
Application number
SE7604052A
Other languages
English (en)
Other versions
SE7604052L (sv
Inventor
R Maier
E Woitun
B Wetzel
W Reuter
H Goeth
U Lechner
Original Assignee
Thomae Gmbh Dr K
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25768725&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE425566(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE2515075A external-priority patent/DE2515075C2/de
Priority claimed from DE19762606030 external-priority patent/DE2606030A1/de
Application filed by Thomae Gmbh Dr K filed Critical Thomae Gmbh Dr K
Publication of SE7604052L publication Critical patent/SE7604052L/sv
Publication of SE425566B publication Critical patent/SE425566B/sv

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08Hetero rings containing eight or more ring members, e.g. erythromycins

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SE7604052A 1975-04-07 1976-04-06 Forfarande for framstellning av erytromycinderivat och syraadditionssalter derav SE425566B (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE2515075A DE2515075C2 (de) 1975-04-07 1975-04-07 Erythromycinderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19762606030 DE2606030A1 (de) 1976-02-14 1976-02-14 Neue erythromycinderivate und verfahren zu ihrer herstellung

Publications (2)

Publication Number Publication Date
SE7604052L SE7604052L (sv) 1976-10-08
SE425566B true SE425566B (sv) 1982-10-11

Family

ID=25768725

Family Applications (1)

Application Number Title Priority Date Filing Date
SE7604052A SE425566B (sv) 1975-04-07 1976-04-06 Forfarande for framstellning av erytromycinderivat och syraadditionssalter derav

Country Status (29)

Country Link
US (1) US4048306A (sv)
JP (1) JPS51128991A (sv)
AT (1) AT342770B (sv)
AU (1) AU498418B2 (sv)
BG (1) BG27380A3 (sv)
CA (1) CA1060005A (sv)
CH (2) CH621800A5 (sv)
CS (1) CS196304B2 (sv)
DD (1) DD125218A5 (sv)
DK (1) DK138656C (sv)
ES (2) ES446737A1 (sv)
FI (1) FI63244C (sv)
FR (1) FR2306703A1 (sv)
GB (1) GB1520963A (sv)
GR (1) GR60374B (sv)
HU (1) HU175186B (sv)
IE (1) IE43598B1 (sv)
IL (1) IL49359A (sv)
LU (2) LU88563I2 (sv)
MX (1) MX3277E (sv)
NL (1) NL180107C (sv)
NO (1) NO141411C (sv)
NZ (1) NZ180529A (sv)
PL (1) PL101880B1 (sv)
PT (1) PT64977B (sv)
RO (1) RO68441B (sv)
SE (1) SE425566B (sv)
SU (1) SU682134A3 (sv)
YU (1) YU87676A (sv)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES552858A1 (es) 1985-03-12 1987-11-01 Beecham Group Plc Un procedimiento para la preparacion de derivados de eritromicina.
DE3524572A1 (de) * 1985-07-10 1987-01-15 Thomae Gmbh Dr K Feste arzneimittelformen zur peroralen anwendung enthaltend 9-deoxo-11-deoxy-9,11-(imino(2-(2-methoxyethoxy)ethyliden)-oxy)-(9s)-erythromycin und verfahren zu ihrer herstellung
US5110800A (en) * 1986-02-18 1992-05-05 Eli Lilly And Company Derivatives of erythromycylamine
US4945080A (en) * 1987-05-26 1990-07-31 Eli Lilly And Company Dirithromycin metabolite
US5075289A (en) * 1988-06-07 1991-12-24 Abbott Laboratories 9-r-azacyclic erythromycin antibiotics
EP0559896B1 (en) * 1990-11-28 1997-08-27 Taisho Pharmaceutical Co. Ltd 6-o-methylerythromycin a derivative
ZA922777B (en) * 1991-04-29 1993-10-15 Lilly Co Eli Pharmaceutical formulation containing dirithromycin
US5556839A (en) * 1991-04-29 1996-09-17 Eli Lilly And Company Form II Dirithromycin
CZ281664B6 (cs) * 1991-09-30 1996-12-11 Eli Lilly And Company Patent Division Lilly Corporate Center Způsob jednostupňové přípravy dirithromycinu
DE4410637C1 (de) * 1994-03-26 1995-09-21 Boehringer Ingelheim Vetmed Injizierbare Lösungen von Dirithromycin
WO1999021867A1 (fr) * 1997-10-29 1999-05-06 Taisho Pharmaceutical Co., Ltd. Derives d'erythromycine a
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6436906B1 (en) 2001-04-02 2002-08-20 Enanta Pharmaceuticals, Inc. 9-amino-14-membered macrolides derived from leucomycins
AU2004258949B2 (en) 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
CA2533292C (en) 2003-07-21 2013-12-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
AU2004258944B2 (en) 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
JP2007502296A (ja) 2003-08-11 2007-02-08 アドバンシス ファーマスーティカル コーポレイション ロバストペレット
US8062672B2 (en) 2003-08-12 2011-11-22 Shionogi Inc. Antibiotic product, use and formulation thereof
WO2005023184A2 (en) * 2003-08-29 2005-03-17 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
WO2005027877A1 (en) 2003-09-15 2005-03-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
WO2006014427A1 (en) 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8299052B2 (en) * 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3660376A (en) * 1970-09-30 1972-05-02 Lilly Co Eli N-arylidene erythromycylamines

Also Published As

Publication number Publication date
BG27380A3 (en) 1979-10-12
SE7604052L (sv) 1976-10-08
IL49359A0 (en) 1976-06-30
NL180107C (nl) 1987-01-02
MX3277E (es) 1980-08-15
IE43598L (en) 1976-10-07
NL7603569A (nl) 1976-10-11
HU175186B (hu) 1980-05-28
PT64977A (de) 1976-05-01
RO68441A (ro) 1983-04-29
DK138656B (da) 1978-10-09
PL101880B1 (pl) 1979-02-28
PT64977B (de) 1978-04-03
SU682134A3 (ru) 1979-08-25
NO141411B (no) 1979-11-26
FR2306703A1 (fr) 1976-11-05
ES446737A1 (es) 1977-10-16
US4048306A (en) 1977-09-13
GR60374B (en) 1978-05-23
IE43598B1 (en) 1981-04-08
GB1520963A (en) 1978-08-09
CH624413A5 (sv) 1981-07-31
CH621800A5 (sv) 1981-02-27
NL180107B (nl) 1986-08-01
LU74702A1 (sv) 1977-06-03
RO68441B (ro) 1983-04-30
YU87676A (en) 1982-08-31
IL49359A (en) 1979-07-25
AT342770B (de) 1978-04-25
NZ180529A (en) 1978-09-20
FI760845A (sv) 1976-10-08
FR2306703B1 (sv) 1979-10-12
ATA149976A (de) 1977-08-15
FI63244B (fi) 1983-01-31
FI63244C (fi) 1983-05-10
JPS62158B2 (sv) 1987-01-06
AU498418B2 (en) 1979-03-15
NO141411C (no) 1980-03-05
CS196304B2 (en) 1980-03-31
DD125218A5 (de) 1977-04-06
DK145276A (da) 1976-10-08
JPS51128991A (en) 1976-11-10
NO761172L (sv) 1976-10-08
DK138656C (da) 1979-04-02
LU88563I2 (fr) 1995-03-21
AU1272276A (en) 1977-10-13
CA1060005A (en) 1979-08-07
ES456567A1 (es) 1978-03-01

Similar Documents

Publication Publication Date Title
SE425566B (sv) Forfarande for framstellning av erytromycinderivat och syraadditionssalter derav
SE7613565L (sv) Forfarande for framstellning av fusidinsyraderivat
NO821848L (no) Fremgangsmaate for fremstilling av gamma-pyron-derivater
SE421319B (sv) Forfarande for framstellning av etbara polysackarider och polysackaridderivat
SE422937B (sv) Forfarande for framstellning av nya propagyl-2-fenylaminoimidazolin-(2) och deras syraadditionssalter
SE7613839L (sv) Forfarande for framstellning av 2(1h)-kinazolinonderivat
SE7707407L (sv) Forfarande for framstellning av cefamderivat
SE440080B (sv) Forfarande for framstellning av klavulansyraderivat
SE428688B (sv) Forfarande for framstellning av nya antidiabetiskt aktiva isooxazolderivat
SE7611504L (sv) Tiazolidinderivat och forfarande for deras framstellning
SE432424B (sv) Halogenerade alkoxisilanforeningar och forfarande for deras framstellning
SE7509897L (sv) Basiskt substituerade 3-sulfamoylbensoesyraderivat och forfarande for deras framstellning
SE404186B (sv) Forfarande for framstellning av cyklopropanolderivat
SE422936B (sv) Forfarande for framstellning av substituerade 2-alkylamino-4-fenylimidazoliner och deras syraadditionssalter
SE423814B (sv) Forfarande for framstellning av dibensofenazin- eller acenaftokinoxalinderivat
SE7614091L (sv) Forfarande for framstellning av tiadiazolylderivat av 7-acylamido-3-cefem-4-karbonsyra
SE7606815L (sv) Forfarande for framstellning av nya naftacenderivat
SE7600704L (sv) Difenyleter-derivat och forfarande for framstellning derav
SE7607322L (sv) Forfarande for framstellning av 16-etrar av fusidinsyraderivat
SE7607026L (sv) Forfarande for framstellning av 5-alkylpikolinsyra
SE7808849L (sv) Forfarande for framstellning av 9,11,15-trihydroxi-13,14-dehydroprostaglandiner och prost-5-en-13-ynsyraderivat
SE406586B (sv) Nytt forfarande for framstellning av 3-fenyl-indol-2-sarbonitril och derivat derav
SE7604879L (sv) 7-metoxicefalosporinderivat och forfarande for framstellning derav
SE427037B (sv) Forfarande for framstellning av deoxiklavulansyra
SE411756B (sv) Forfarande for framstellning av fenotiaziner, fenoxaziner och akridan-bis-pyrrolinylderivat

Legal Events

Date Code Title Description
NAL Patent in force

Ref document number: 7604052-6

Format of ref document f/p: F

NUG Patent has lapsed

Ref document number: 7604052-6

Format of ref document f/p: F